Navigation Links
Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain
Date:9/23/2011

result in overdose and death.Summary of Clinical StudyPatients evaluated in this randomized, double-blind, double-dummy active controlled, superiority study had moderate-to-severe low back pain for at least three months and were receiving treatment with opioid analgesics at doses between 30 to 80 mg of morphine sulfate or the equivalent at least four days per week for at least 30 days prior to the screening visit.  Sixty-two percent (62%) of patients were taking hydrocodone-containing medications; 21% were taking oxycodone-containing medications; and 12% of patients were taking propoxyphene-containing medications.  Prospective patients were excluded if they were currently using the fentanyl transdermal-system, extended-release hydromorphone, or more than 80 mg per day of oral morphine equivalent for pain control upon entry into the study.

The study employed an enriched design – allowing only patients who both tolerated and responded to Butrans during an open label run-in period to enter into the 12-week double-blind phase of the trial, mimicking the treatment of patients in a clinical practice setting.  

The efficacy and safety of Butrans 20 mcg/hour was assessed using Butrans 5 mcg/hour as the low-dose control group.  All patients wore either active or placebo patches (double-dummy technique).  The study was performed at 75 centers in the United States.

Of the 1160 patients that entered the open-label run-in period, 57% were able to titrate to and tolerate the adverse effects of Butrans 20 mcg/hour and were randomized into a 12-week double-blind treatment phase.  Twelve percent (12%) of patients discontinued due to an adverse event and 21% discontinued due to lack of a therapeutic effect during the open-label titration period. A total of 660 patients were randomized to the double-blind phase to receive Butrans 20 mcg/hour, Butrans 5 mcg/hour, or an active control, for 12 weeks.  During the double-blind t
'/>"/>

SOURCE Purdue Pharma L.P.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. AIMs Program for Improving Echocardiography Appropriateness Yields Impressive Results
2. Misonix Reports Fourth Quarter and Year-End Fiscal 2011 Financial Results
3. Accuray Announces Results for Fourth Quarter and Fiscal Year 2011
4. Misonix Schedules Fourth Quarter and Year-End Fiscal 2011 Financial Results Conference Call; September 20, 2011 at 4:30 p.m. Eastern
5. Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD
6. Pro-Dex, Inc. Announces Fiscal 2011 Fourth Quarter and Full-Year Results
7. Intarcia Presents Compelling 48-week Results for ITCA 650 - Data Underlines the Promise to Become the First Injection-free GLP-1 Therapy at the 47th Annual EASD Meeting in Lisbon
8. ResMed Announces Conference Call and Webcast to Discuss First Quarter 2012 Results
9. Champions Oncology Reports Fiscal 2012 First Quarter Financial Results
10. Innocoll Announces Top-line Results from its Phase 2 Clinical Trial Investigating XaraColl® for the Management of Post-operative Pain and Receives "Notice of Allowability" for XaraColl U.S. Patent Application
11. Positive Results From Avanafil Phase 3 Study in Diabetics Presented at the 47th EASD Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
(Date:1/14/2014)... InformEx, North America,s leading business partnering ... the 30 th edition of its annual conference at ... January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... and specialty chemical companies will take part in the conference, ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... CVS Caremark Corporation (NYSE: CVS ), today announced ... ended September 30, 2011. (Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO) ... Net revenues increased 12.5% to a record $26.7 billion ... Retail Pharmacy segment revenues increased 3.8%, with same ...
... Bellicum Pharmaceuticals, Inc. today announced publication in ... results using a new therapy that demonstrated rapid and ... Inducible Apoptosis as a Safety Switch for Adoptive Cell ... ™ technology to eliminate donor T cells causing ...
Cached Medicine Technology:CVS Caremark Reports Third Quarter Results 2CVS Caremark Reports Third Quarter Results 3CVS Caremark Reports Third Quarter Results 4CVS Caremark Reports Third Quarter Results 5CVS Caremark Reports Third Quarter Results 6CVS Caremark Reports Third Quarter Results 7CVS Caremark Reports Third Quarter Results 8CVS Caremark Reports Third Quarter Results 9CVS Caremark Reports Third Quarter Results 10CVS Caremark Reports Third Quarter Results 11CVS Caremark Reports Third Quarter Results 12CVS Caremark Reports Third Quarter Results 13CVS Caremark Reports Third Quarter Results 14CVS Caremark Reports Third Quarter Results 15Bellicum Announces Publication in The New England Journal of Medicine Demonstrating Complete Reversal of Serious Immune Condition in Hematopoietic Stem Cell Transplant Patients 2Bellicum Announces Publication in The New England Journal of Medicine Demonstrating Complete Reversal of Serious Immune Condition in Hematopoietic Stem Cell Transplant Patients 3Bellicum Announces Publication in The New England Journal of Medicine Demonstrating Complete Reversal of Serious Immune Condition in Hematopoietic Stem Cell Transplant Patients 4
(Date:4/23/2014)... "simple and accessible detection methods that can rapidly ... of a single cell inside that population has ... Chang Lu. , In the Royal Society of ... announced that he and his coworkers have developed ... of a protein ( Chem. Sci. , 2014, ...
(Date:4/23/2014)... are often displayed in the popular Swedish children,s ... of high-sugar foods. A new study from the ... in children,s TV programmes as well as the ... and weight status. , Steingerdur Olafsdottir,s doctoral thesis ... popular Swedish children,s TV show Bolibompa. Healthy foods ...
(Date:4/23/2014)... led by a researcher from the Cancer Science Institute ... Singapore has identified the cancer specific stem cell which ... of developing new drugs for the treatment of this ... group, led by Dr Chan Shing Leng, Research Assistant ... that a cancer-specific variant of a cell surface protein, ...
(Date:4/23/2014)... in the journal Oncotarget , explored tumour ... or their own DNA signatures within the same ... design effective, targeted treatment strategies. , Firstly they ... and either the KRAS or BRAF mutation. Secondly, ... EGFR gene mutation have that specific mutation present ...
(Date:4/23/2014)... Alzheimer,s disease has been a rapidly evolving pursuit ... latest crook in the research road, scientists have ... proteins associated with the disease. The report, which ... , could have important implications for developing novel ... colleagues explain that for years, research has suggested ...
Breaking Medicine News(10 mins):Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:High-calorie and low-nutrient foods in kids' TV 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2
... Wash., June 11 Following a two-year clinical ... , Stayhealthy introduced their next generation body composition ... The technology accurately measures body composition, comes in ... a home use individual device, to a commercial ...
... , , Continued Market Share Increase Combined with ... SAN BRUNO, Calif., June 11 Cord Blood Registry ... stem cells from umbilical cord blood, reported solid revenue growth in ... 2008. Earnings for the quarter showed even stronger gains due ...
... ... help parents combat teen drug use, is now available from Bartell Drugs , ... Seattle, CA (Vocus) June 11, 2009 -- HairConfirm, a new ... from Bartell Drugs. The kit detects drug use for up to 90 days by analyzing ...
... ... of British Heart week (8-15th June), Dr Jav Nazemi - CEO of Igennus, ... condition led to the start of his business and the omega-3 EPA formula, ... pence per tub sold this week to the Children,s Heart Federation, in order ...
... ... is a struggle for women of all ages. Despite the turmoil of ... for symptomatic relief of menstrual and menopausal woes. Garden of Life, Inc., ... women of all ages a natural way to balance hormones with the ...
... 10 The following statement was issued Wednesday, June ... Jessie M. Pavlinac, following a press conference by U.S. ... restaurant menu labeling to be included in the Senate,s ... health-care reform legislation. , , "The American Dietetic ...
Cached Medicine News:Health News:New Stayhealthy Body Composition Technology Announced at Microsoft's Connected Health Conference 2Health News:New Stayhealthy Body Composition Technology Announced at Microsoft's Connected Health Conference 3Health News:Cord Blood Registry Maintains Solid Growth in First Quarter 2009 2Health News:Cord Blood Registry Maintains Solid Growth in First Quarter 2009 3Health News:New Home Drug Hair Test Kit Now Available from Bartell Drugs; ,HairConfirm Detects 90-Day Drug Use & Usage Frequency 2Health News:Omega-3 EPA: Treatment for a Heart Condition 2Health News:Omega-3 EPA: Treatment for a Heart Condition 3Health News:Omega-3 EPA: Treatment for a Heart Condition 4Health News:Omega-3 EPA: Treatment for a Heart Condition 5Health News:Omega-3 EPA: Treatment for a Heart Condition 6Health News:MORE WOMEN SHUN HORMONE REPLACEMENT THERAPY Garden of Life Offers a Natural Solution with Oceans 3™ Healthy Hormones™ 2Health News:MORE WOMEN SHUN HORMONE REPLACEMENT THERAPY Garden of Life Offers a Natural Solution with Oceans 3™ Healthy Hormones™ 3Health News:MORE WOMEN SHUN HORMONE REPLACEMENT THERAPY Garden of Life Offers a Natural Solution with Oceans 3™ Healthy Hormones™ 4Health News:Statement by American Dietetic Association Supporting Scientifically Valid, Informative Restaurant Labeling as Part of Health Reform 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: